MCID: PRN020
MIFTS: 43

Paranasal Sinus Cancer

Categories: Cancer diseases, Respiratory diseases, Skin diseases, Rare diseases

Aliases & Classifications for Paranasal Sinus Cancer

MalaCards integrated aliases for Paranasal Sinus Cancer:

Name: Paranasal Sinus Cancer 12 15 73
Paranasal Sinus Adenoid Cystic Carcinoma 12 73
Paranasal Sinus Mucoepidermoid Carcinoma 12 73
Paranasal Sinus Squamous Cell Carcinoma 12 73
Paranasal Sinus Neoplasms 44 73
Adenoid Cystic Carcinoma of Accessory Sinus 12
Adenoid Cystic Carcinoma of Paranasal Sinus 12
Epidermoid Carcinoma of the Paranasal Sinus 12
Mucoepidermoid Carcinoma of Accessory Sinus 12
Squamous Cell Carcinoma of Paranasal Sinus 12
Adenocarcinoma of Accessory Sinus 73
Paranasal Sinus Adenocarcinoma 12

Classifications:



Summaries for Paranasal Sinus Cancer

Disease Ontology : 12 A respiratory system cancer that is located in the paranasal sinuses.

MalaCards based summary : Paranasal Sinus Cancer, also known as paranasal sinus adenoid cystic carcinoma, is related to paranasal sinus cancer, adult and paranasal sinus cancer, childhood, and has symptoms including pain and rhinorrhea. An important gene associated with Paranasal Sinus Cancer is MALL (Mal, T Cell Differentiation Protein Like), and among its related pathways/superpathways is Antigen Presentation- Folding, assembly and peptide loading of class I MHC. The drugs Tegafur and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include the paranasal sinuses, lung and brain.

Related Diseases for Paranasal Sinus Cancer

Diseases in the Paranasal Sinus Cancer family:

Paranasal Sinus Cancer, Adult

Diseases related to Paranasal Sinus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 12)
# Related Disease Score Top Affiliating Genes
1 paranasal sinus cancer, adult 12.2
2 paranasal sinus cancer, childhood 12.2
3 sinus cancer 10.5
4 adenoiditis 10.1
5 adenoid cystic carcinoma 10.1
6 squamous cell carcinoma 10.0
7 inverted papilloma 10.0
8 nasopharyngitis 9.8
9 papilloma 9.8
10 schneiderian carcinoma 9.5 MAML2 SOX4
11 maxillary sinus squamous cell carcinoma 9.2 PDIA3 TAPBP
12 maxillary sinus cancer 6.5 LDHB MALL MAML2 PDIA3 SOX4 TAPBP

Graphical network of the top 20 diseases related to Paranasal Sinus Cancer:



Diseases related to Paranasal Sinus Cancer

Symptoms & Phenotypes for Paranasal Sinus Cancer

UMLS symptoms related to Paranasal Sinus Cancer:


pain, rhinorrhea

Drugs & Therapeutics for Paranasal Sinus Cancer

Drugs for Paranasal Sinus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 214)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
2
Cisplatin Approved Phase 3,Phase 1,Phase 2,Not Applicable 15663-27-1 84093 441203 2767
3
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
4
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
5
Racepinephrine Approved Phase 3,Phase 2 329-65-7 838
6
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2 33069-62-4 36314
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
9
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
10
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
11
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
12
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
13
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
14
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
15
Cetuximab Approved Phase 3,Phase 2,Phase 1,Not Applicable 205923-56-4 56842117 2333
16
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
17
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
18
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
19
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
20
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
22
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
23 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
24 Antimetabolites Phase 3,Phase 1,Phase 2
25 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
26
s 1 (combination) Phase 3
27 Adrenergic Agents Phase 3,Phase 2
28 Adrenergic Agonists Phase 3,Phase 2
29 Adrenergic alpha-Agonists Phase 3,Phase 2
30 Adrenergic beta-Agonists Phase 3,Phase 2
31 Anti-Asthmatic Agents Phase 3,Phase 2
32 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
33 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
34 Autonomic Agents Phase 3,Phase 2,Not Applicable
35 Bronchodilator Agents Phase 3,Phase 2
36 Epinephryl borate Phase 3,Phase 2
37 Mydriatics Phase 3,Phase 2
38 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
39 Peripheral Nervous System Agents Phase 3,Phase 2,Not Applicable
40 Respiratory System Agents Phase 3,Phase 2
41 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
42 Vasoconstrictor Agents Phase 3,Phase 2
43 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
44 Anti-Infective Agents Phase 2, Phase 3,Phase 1,Not Applicable
45 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
46 Albumin-Bound Paclitaxel Phase 3,Phase 1,Phase 2
47 Antimitotic Agents Phase 3,Phase 1,Phase 2
48 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
49 Immunosuppressive Agents Phase 3,Phase 1,Phase 2,Not Applicable
50 Antirheumatic Agents Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 180)
# Name Status NCT ID Phase Drugs
1 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
2 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
5 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
6 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
7 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
8 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
9 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
10 Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002888 Phase 3 cisplatin;fluorouracil;paclitaxel
11 Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00003809 Phase 3 cisplatin
12 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
13 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
14 Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery Completed NCT00003576 Phase 3 cisplatin;fluorouracil
15 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
16 Treatment of Malignant Sinonasal Tumours With Intensity-modulated Radiotherapy (IMRT) and Carbon Ion Boost (C12) Unknown status NCT01220752 Phase 2
17 Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
18 Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
19 Radiation Therapy Following Surgery in Treating Patients With Recurrent or Second Primary Cancer of the Head and Neck Following Previous Radiation Therapy Unknown status NCT00004226 Phase 1, Phase 2
20 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
21 Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00003257 Phase 2
22 Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy Unknown status NCT00003856 Phase 2 temoporfin
23 Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00022217 Phase 2 carboplatin;cisplatin-e therapeutic implant;paclitaxel
24 Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
25 Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00513435 Phase 2 saracatinib
26 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Completed NCT00939627 Phase 2 sorafenib tosylate
27 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
28 Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00507767 Phase 2 dasatinib
29 Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
30 Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00114283 Phase 2 lapatinib ditosylate
31 S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
32 SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00095628 Phase 2 ispinesib
33 Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
34 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
35 Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer Completed NCT00055770 Phase 1, Phase 2 erlotinib hydrochloride;docetaxel
36 Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
37 Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer Completed NCT00387335 Phase 2 sunitinib malate
38 Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer Completed NCT00098631 Phase 2 lapatinib ditosylate
39 Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00055913 Phase 1, Phase 2 erlotinib hydrochloride
40 Paclitaxel, Cisplatin, and Filgrastim Combined With Radiation Therapy in Treating Patients With Locally Recurrent Head and Neck Cancer Completed NCT00005087 Phase 2 cisplatin;paclitaxel
41 EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer Completed NCT00049140 Phase 2 EF5
42 Arginine/Omega-3 Fatty Acids/Nucleotides Nutritional Supplement in Treating Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy Completed NCT00559156 Phase 2 cisplatin
43 Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer Completed NCT00006033 Phase 2 methotrexate
44 Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer Completed NCT00004070 Phase 1, Phase 2
45 Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00005814 Phase 2 cisplatin
46 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
47 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
48 Oxaliplatin in Treating Patients With Advanced Head and Neck Cancer Completed NCT00005035 Phase 2 oxaliplatin
49 Randomized Amifostine For SCCHN Completed NCT00095927 Phase 2 Amifostine;Carboplatin;Paclitaxel
50 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2 docetaxel

Search NIH Clinical Center for Paranasal Sinus Cancer

Cochrane evidence based reviews: paranasal sinus neoplasms

Genetic Tests for Paranasal Sinus Cancer

Anatomical Context for Paranasal Sinus Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Paranasal Sinus Cancer:

19
The Paranasal Sinuses

MalaCards organs/tissues related to Paranasal Sinus Cancer:

41
Lung, Brain, Liver, Lymph Node, Breast, Kidney, Skin

Publications for Paranasal Sinus Cancer

Articles related to Paranasal Sinus Cancer:

(show all 29)
# Title Authors Year
1
Prognostic value of pretreatment peripheral blood markers in paranasal sinus cancer: Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio. ( 28032937 )
2016
2
Estimation of the planning organ at risk volume for the lenses during radiation therapy for nasal cavity and paranasal sinus cancer. ( 26238510 )
2015
3
Paranasal sinus cancer. ( 26520459 )
2015
4
A dosimetric comparison of volumetric modulated arc therapy (VMAT) and non-coplanar intensity modulated radiotherapy (IMRT) for nasal cavity and paranasal sinus cancer. ( 25175383 )
2014
5
Dose distribution resulting from changes in aeration of nasal cavity or paranasal sinus cancer in the proton therapy. ( 25245554 )
2014
6
Cranial Nerves Contouring Among Patients Treated With IMRT for Base of Skull, Nasopharyngeal, and Paranasal Sinus Cancer. ( 24674554 )
2013
7
Significant improvement in superselective intra-arterial chemotherapy for advanced paranasal sinus cancer by using indocyanine green fluorescence. ( 24318470 )
2013
8
Paranasal sinus cancer. ( 23523040 )
2013
9
Non-coplanar volumetric modulated arc therapy for irradiation of paranasal sinus tumors: in response to Al-Mamgani et al., Highly-conformal intensity-modulated radiotherapy reduced toxicity without jeopardizing outcome in patients with paranasal sinus cancer treated by surgery and radiotherapy or (chemo)radiation. Oral Oncol 2012;48(9):905-11. ( 23218179 )
2013
10
Highly-conformal intensity-modulated radiotherapy reduced toxicity without jeopardizing outcome in patients with paranasal sinus cancer treated by surgery and radiotherapy or (chemo)radiation. ( 22584070 )
2012
11
Fistula formation after postoperative radiation treatment for paranasal sinus cancer. ( 18391607 )
2008
12
Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting--the MSKCC experience. ( 17161557 )
2007
13
A dosimetric comparison of non-coplanar IMRT versus Helical Tomotherapy for nasal cavity and paranasal sinus cancer. ( 17275112 )
2007
14
Intra-arterial cisplatin and concomitant radiation therapy followed by surgery for advanced paranasal sinus cancer. ( 15313865 )
2004
15
The delivery of IMRT with a single physical modulator for multiple fields: a feasibility study for paranasal sinus cancer. ( 14967445 )
2004
16
Paranasal sinus cancer. ( 15185004 )
2004
17
Paranasal sinus cancer: caveats and controversies. ( 14509518 )
2003
18
Invasive surgery for paranasal sinus cancer: is there still any indication for lateral rhinotomy and non endoscopic approaches? ( 10635392 )
1999
19
Combined-modality therapy in paranasal sinus cancer. ( 10439164 )
1999
20
p53 alteration and human papilloma virus infection in paranasal sinus cancer. ( 9083153 )
1997
21
Prognostic factors in paranasal sinus cancer. ( 7793504 )
1995
22
Treatment of paranasal sinus cancer with cranial base surgery: results. ( 8189985 )
1994
23
Craniofacial resection in the management of paranasal sinus cancer. ( 18638740 )
1994
24
Subdural hematoma associated with dural metastasis from paranasal sinus cancer: a case report and review of the literature. ( 8336926 )
1993
25
Paranasal sinus cancer. ( 2018438 )
1991
26
Preservation of the eye in paranasal sinus cancer surgery. ( 2914102 )
1989
27
Preservation of the eye in paranasal sinus cancer surgery. ( 2835065 )
1988
28
Craniofacial resection for paranasal sinus cancer with free flap repair. ( 3466583 )
1986
29
The use of acrylic resin oral prosthesis in radiation therapy of oral cavity and paranasal sinus cancer. ( 6288635 )
1982

Variations for Paranasal Sinus Cancer

Cosmic variations for Paranasal Sinus Cancer:

9
(show all 18)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM45025 TP53 upper aerodigestive tract,sinus,carcinoma,adenocarcinoma c.488A>C p.Y163S 17:7675124-7675124 23
2 COSM10768 TP53 upper aerodigestive tract,sinus,carcinoma,adenocarcinoma c.535C>T p.H179Y 17:7675077-7675077 23
3 COSM10667 TP53 upper aerodigestive tract,sinus,carcinoma,adenocarcinoma c.646G>A p.V216M 17:7674885-7674885 23
4 COSM11286 TP53 upper aerodigestive tract,sinus,carcinoma,adenocarcinoma c.1015G>T p.E339* 17:7670694-7670694 23
5 COSM43606 TP53 upper aerodigestive tract,sinus,carcinoma,adenocarcinoma c.734G>A p.G245D 17:7674229-7674229 23
6 COSM11166 TP53 upper aerodigestive tract,sinus,carcinoma,adenocarcinoma c.406C>T p.Q136* 17:7675206-7675206 23
7 COSM10654 TP53 upper aerodigestive tract,sinus,carcinoma,adenocarcinoma c.637C>T p.R213* 17:7674894-7674894 23
8 COSM10645 TP53 upper aerodigestive tract,sinus,carcinoma,adenocarcinoma c.527G>T p.C176F 17:7675085-7675085 23
9 COSM10662 TP53 upper aerodigestive tract,sinus,carcinoma,adenocarcinoma c.743G>A p.R248Q 17:7674220-7674220 23
10 COSM10648 TP53 upper aerodigestive tract,sinus,carcinoma,adenocarcinoma c.524G>A p.R175H 17:7675088-7675088 23
11 COSM10656 TP53 upper aerodigestive tract,sinus,carcinoma,adenocarcinoma c.742C>T p.R248W 17:7674221-7674221 23
12 COSM45026 TP53 upper aerodigestive tract,sinus,carcinoma,adenocarcinoma c.560-2A>T p.? 17:7674973-7674973 23
13 COSM44972 TP53 upper aerodigestive tract,sinus,carcinoma,adenocarcinoma c.831T>A p.C277* 17:7673789-7673789 23
14 COSM44948 TP53 upper aerodigestive tract,sinus,carcinoma,adenocarcinoma c.526T>C p.C176R 17:7675086-7675086 23
15 COSM43650 TP53 upper aerodigestive tract,sinus,carcinoma,adenocarcinoma c.638G>T p.R213L 17:7674893-7674893 23
16 COSM10663 TP53 upper aerodigestive tract,sinus,carcinoma,adenocarcinoma c.916C>T p.R306* 17:7673704-7673704 23
17 COSM521 KRAS upper aerodigestive tract,sinus,carcinoma,adenocarcinoma c.35G>A p.G12D 12:25245350-25245350 23
18 COSM483 HRAS upper aerodigestive tract,sinus,carcinoma,adenocarcinoma c.35G>T p.G12V 11:534288-534288 23

Expression for Paranasal Sinus Cancer

Search GEO for disease gene expression data for Paranasal Sinus Cancer.

Pathways for Paranasal Sinus Cancer

Pathways related to Paranasal Sinus Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.02 PDIA3 TAPBP

GO Terms for Paranasal Sinus Cancer

Cellular components related to Paranasal Sinus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myelin sheath GO:0043209 8.62 LDHB PDIA3

Biological processes related to Paranasal Sinus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 8.96 PDIA3 TAPBP
2 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 8.62 PDIA3 TAPBP

Sources for Paranasal Sinus Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....